Senators Scrutinize Mylan Over EpiPen’s U.S. Price IncreasesBy and
Grassley asks drugmaker to provide information on pricing
Klobuchar calls for FTC to look into business practices
Two senior U.S. senators are examining Mylan NV’s price increases for the popular EpiPen allergy shot, with lawmakers saying the drugmaker’s practices may have limited competition and access to the treatment.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.